Toggle navigation menu
Home
About
Acorda
Company
Leadership
Management Team
Board of Directors
Partnering
With Acorda
Grant
Program
Scientific
Award
Compliance
Acorda Compliance
Biotie EFPIA Discolsures
Message From
BIO
Diversity and
Inclusion
Contact Us
For
Patients
Focus On
Therapies
In the
Community
Resources
Policy on Access to
Unapproved Medicines
Products &
Research
Pipeline
ARCUS® Technology
Products
AMPYRA®
(dalfampridine)
INBRIJA™
(levodopa inhalation powder)
Clinical
Trials
Research &
Development
BTT1023
(timolumab)
CVT-427
rHIgM22
Investors
Corporate
Governance
Stock
Information
Investor Events
Investor News
Financial
Information
Quarterly Updates
Annual Reports
SEC Filings
Analysts
Investor
Resources
Investor Kit
E-mail Alerts
FAQs
IR Contact
News &
Events
In the News
Awards
Press Releases
Social Media
Careers
Working at
Acorda
Our
Employees
Benefits
Job Openings
Internship
Program
Application
Home
About
Acorda
Company
Leadership
Management Team
Board of Directors
Partnering
With Acorda
Grant
Program
Scientific
Award
Compliance
Acorda Compliance
Biotie EFPIA Discolsures
Message From
BIO
Diversity and
Inclusion
Contact Us
For
Patients
Focus On
Therapies
In the
Community
Resources
Policy on Access to
Unapproved Medicines
Products &
Research
Pipeline
ARCUS® Technology
Products
AMPYRA®
(dalfampridine)
INBRIJA™
(levodopa inhalation powder)
Clinical
Trials
Research &
Development
BTT1023
(timolumab)
CVT-427
rHIgM22
Investors
Corporate
Governance
Stock
Information
Investor Events
Investor News
Financial
Information
Quarterly Updates
Annual Reports
SEC Filings
Analysts
Investor
Resources
Investor Kit
E-mail Alerts
FAQs
IR Contact
News &
Events
In the News
Awards
Press Releases
Social Media
Careers
Working at
Acorda
Our
Employees
Benefits
Job Openings
Internship
Program
Application
Privacy Policy
Terms Of Use
Site Map
Contact Us
SEC Filings Details
10/24/12
4
Statement of Changes in Beneficial Ownership
Quick Links
View our investor kit
MEET OUR LEADERSHIP TEAM
Board Of Directors
Contact Us
Pipeline
SEC Filings
Email Alerts
Un-subscribe from email alerts
Email Address
*
Mailing Lists
*
News Releases Alert
SEC Alert
Events Alert
Calendar Alert
Enter the code shown above.
Text size
Normal
Larger
Largest
Print
ABOUT ACORDA
Company Leadership
Management Team
Board of Directors
Partnering With Acorda
Grant Program
Scientific Award
Compliance
Acorda Compliance
Biotie EFPIA Discolsures
Message From BIO
Diversity and Inclusion
Contact Us
FOR PATIENTS
Focus On Therapies
In The Community
Resources
Policy on Access to
Unapproved Medicines
PRODUCTS & RESEARCH
Pipeline
ARCUS® Technology
Products
AMPYRA®
(dalfampridine)
INBRIJA™
(levodopa inhalation powder)
Clinical Trials
Research & Development
BTT1023 (timolumab)
CVT-427
rHIgM22
INVESTORS
Corporate Governance
Stock Information
Investors Events
Investor News
Financial Information
Quarterly Reports
Annual Reports
SEC Filings
Analysts
Investor Resources
Investor Kit
E-mail Alerts
FAQs
IR Contact
NEWS & EVENTS
In The News
Awards
Investor News
Social Media
CAREERS
Working At Acorda
Our Employees
Benefits
Job Openings
Internship Program
Application
Home
|
Privacy Policy
|
Terms Of Use
|
Site Map
|
Contact Us
© Copyright 2017
Powered By Q4 Inc.
5.24.1.3